Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. Reardon DA, et al. Among authors: sepulveda jm. JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024. JAMA Oncol. 2020. PMID: 32437507 Free PMC article. Clinical Trial.
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Balana C, et al. Among authors: sepulveda jm. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. J Neurooncol. 2016. PMID: 26847813 Clinical Trial.
Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A, Sepulveda JM, Hernandez-Lain A, Salvador E, Koren L, Manneh R, Ruano Y, Perez-Nuñez A, Lagares A, Ramos A. Hilario A, et al. Among authors: sepulveda jm. Clin Transl Oncol. 2017 Jan;19(1):51-57. doi: 10.1007/s12094-016-1502-4. Epub 2016 Mar 30. Clin Transl Oncol. 2017. PMID: 27026567
Defining EGFR amplification status for clinical trial inclusion.
French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M. French PJ, et al. Among authors: sepulveda jm. Neuro Oncol. 2019 Oct 9;21(10):1263-1272. doi: 10.1093/neuonc/noz096. Neuro Oncol. 2019. PMID: 31125418 Free PMC article.
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, Golfinopoulos V. Van Den Bent M, et al. Among authors: sepulveda jm. Neuro Oncol. 2020 May 15;22(5):684-693. doi: 10.1093/neuonc/noz222. Neuro Oncol. 2020. PMID: 31747009 Free PMC article. Clinical Trial.
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKA, Wen PY, Lassman AB, Joerger M, Tabatabai G, Rodon J, Tiedt R, Zhao S, Kirsilae T, Cheng Y, Vicente S, Balbin OA, Zhang H, Wick W. van den Bent M, et al. J Neurooncol. 2020 Jan;146(1):79-89. doi: 10.1007/s11060-019-03337-2. Epub 2019 Nov 27. J Neurooncol. 2020. PMID: 31776899 Free PMC article. Clinical Trial.
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.
Moreno V, Sepulveda JM, Vieito M, Hernández-Guerrero T, Doger B, Saavedra O, Ferrero O, Sarmiento R, Arias M, De Alvaro J, Di Martino J, Zuraek M, Sanchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Hanna B, Nikolova Z, Braña I. Moreno V, et al. Among authors: sepulveda jm. Ann Oncol. 2020 Jun;31(6):780-788. doi: 10.1016/j.annonc.2020.03.294. Epub 2020 Mar 30. Ann Oncol. 2020. PMID: 32240793 Free article. Clinical Trial.
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis.
Hoogstrate Y, Ghisai SA, de Wit M, de Heer I, Draaisma K, van Riet J, van de Werken HJG, Bours V, Buter J, Vanden Bempt I, Eoli M, Franceschi E, Frenel JS, Gorlia T, Hanse MC, Hoeben A, Kerkhof M, Kros JM, Leenstra S, Lombardi G, Lukacova S, Robe PA, Sepulveda JM, Taal W, Taphoorn M, Vernhout RM, Walenkamp AME, Watts C, Weller M, de Vos FYF, Jenster GW, van den Bent M, French PJ. Hoogstrate Y, et al. Among authors: sepulveda jm. Neuro Oncol. 2022 Mar 12;24(3):429-441. doi: 10.1093/neuonc/noab231. Neuro Oncol. 2022. PMID: 34608482 Free PMC article.
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
Preusser M, Silvani A, Le Rhun E, Soffietti R, Lombardi G, Sepulveda JM, Brandal P, Brazil L, Bonneville-Levard A, Lorgis V, Vauleon E, Bromberg J, Erridge S, Cameron A, Lefranc F, Clement PM, Dumont S, Sanson M, Bronnimann C, Balaná C, Thon N, Lewis J, Mair MJ, Sievers P, Furtner J, Pichler J, Bruna J, Ducray F, Reijneveld JC, Mawrin C, Bendszus M, Marosi C, Golfinopoulos V, Coens C, Gorlia T, Weller M, Sahm F, Wick W. Preusser M, et al. Among authors: sepulveda jm. Neuro Oncol. 2022 May 4;24(5):755-767. doi: 10.1093/neuonc/noab243. Neuro Oncol. 2022. PMID: 34672349 Free PMC article. Clinical Trial.
97 results